Physician profile
Michael Levinson
NPI 1386722437
$1,389.38
in general payments reported to CMS, 2019-2025
11 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $106 · 2021: $157 · 2022: $111 · 2023: $229 · 2024: $247 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $328.33 | 2019-2024 | Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.30 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $138.35 | 2024-2025 | Austedo Xr, Uzedy |
| Johnson & Johnson Vision Care, INC. | $131.53 | 2024 | |
| Genzyme Corporation | $121.83 | 2023 | |
| Dompe US, INC. | $120.06 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $100.95 | 2022-2024 | Infuse |
| Glaukos Corporation | $100.36 | 2019 | |
| Coopervision INC. | $72.50 | 2019-2024 | Myday Contact Lens |
| Carl Zeiss Meditec, INC. | $60.36 | 2019 | |
| Biotissue Holdings INC. | $47.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.